You are now
leaving this site

If you'd like to stay, click CANCEL.
X

Case Study Dr Mehta

Dr Mehta, a Hematologist/Oncologist and leading clinical expert on APDS, explains how Joenja targets the mechanics of APDS to help restore immune balance. He presents a real-life patient case and clinical trial results for Joenja®.

Case Study Dr Hartog

Dr Hartog, a leading allergy and immunology specialist and clinical expert on APDS, discusses a real life patient case and the path to diagnosis, complexities of APDS, clinical trial results for Joenja® and resources to support you and your patients.

Joenja® patient case-vignettes

Explore patients’ experiences with Joenja to gain insights about the treatment and learn how it impacted patients with APDS who were observed for 6 years.

MOA video

Watch Joenja in action and gain a clearer understanding of how Joenja targets the underlying immune defect in APDS.

Get to know our ACEs video

Learn how ACEs get patients started with confidence and partner with them and you throughout the Joenja treatment journey.

Joenja overview for healthcare professionals

A comprehensive brochure providing a brief introduction to APDS, and a detailed description of Joenja that includes an explanation of how Joenja works, the clinical data on the efficacy and safety of Joenja, as well as Joenja dosing and administration information.

Indications and Usage

JOENJA® (leniolisib) is a kinase inhibitor indicated for the treatment of activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) in adult and pediatric patients 12 years of age and older.

Important Safety Information

Verify pregnancy status in females of reproductive potential prior to initiating treatment with JOENJA.

Indications and Usage

JOENJA® (leniolisib) is a kinase inhibitor indicated for the treatment of activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) in adult and pediatric patients 12 years of age and older.

Important Safety Information

Verify pregnancy status in females of reproductive potential prior to initiating treatment with JOENJA.

JOENJA may cause fetal harm when administered to a pregnant woman. Advise patients of the potential risk to a fetus and to use highly effective methods of contraception during treatment with JOENJA and for 1 week after the last dose of JOENJA.

Live, attenuated vaccinations may be less effective if administered during JOENJA treatment.

Use of JOENJA in patients with moderate to severe hepatic impairment is not recommended. There is no recommended dosage for patients weighing less than 45 kg.

The most common adverse reactions (incidence >10%) seen in clinical trials were headache, sinusitis, and atopic dermatitis.

Seven (33%) patients receiving JOENJA developed an absolute neutrophil count (ANC) between 500 and 1500 cells/microL. No patients developed an ANC <500 cells/ microL and there were no reports of infection associated with neutropenia.

Before prescribing JOENJA, please read the full Prescribing Information.